Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
In BriefThis Month in JNM

This Month in JNM

Journal of Nuclear Medicine June 2017, 58 (6) 8A;
  • Article
  • Info & Metrics
  • PDF
Loading

Questioning pediatric dose optimization: Siegel and colleagues evaluate evidence refuting the linear no-threshold model and review studies suggesting that children are not more radiosensitive than adults in the radiologic imaging dose range.

Page 865

Liquid biopsy vs. PET: Wong and colleagues look at the advantages and disadvantages of analysis of circulating tumor DNA and circulating tumor cells and compare the resulting capabilities with those of PET for cancer treatment monitoring and surveillance.

Page 869

Molecular imaging of atherothrombosis: Osborn and colleagues highlight current metabolic and molecular imaging clinical and near-clinical applications in atherosclerosis and venous thromboembolism and describe the potential for metabolic and molecular imaging for individualized risk prediction and disease treatment.

Page 871

Endocrine tumor imaging: Taïeb and colleagues provide commentary and perspective on current PET/CT radiopharmaceuticals targeting endocrine-related cancers, including agents with potential to go beyond localization and more accurately characterize endocrine tumors at the molecular level.

Page 878

Rapid imaging of tumor cell death: Neves and colleagues describe the validation of phosphatidylserine-binding agents labeled with a near-infrared fluorophore, 99mTc, or 111In for detection of tumor cell death based on the C2A domain of synaptotagmin-I.

Page 881

64Cu-/177Lu-labeled anti-EGFR antibody: Laffon and colleagues estimate the kinetic parameters of a diagnostic/therapeutic convergence radiopharmaceutical that acts as an anti–epidermal growth factor receptor in mice bearing esophageal squamous cell carcinoma tumors.

Page 888

CLI for assessing breast tumor margins: Grootendorst and colleagues report on the results of a first-in-human study on the feasibility of 18F-FDG Cerenkov luminescence imaging for intraoperative assessment of tumor margins in breast-conserving surgery.

Page 891

Metabolism and tumor size change: Park and colleagues use CT and 18F-FDG PET to evaluate responses in tumor size and metabolism during chemotherapy for advanced gastric cancer and explore the related effects on patient survival.

Page 899

89Zr-bevacizumab PET and everolimus: van Es and colleagues determine whether 89Zr-bevacizumab PET imaging can identify early disease progression after initiation of everolimus treatment in patients with metastatic renal cell carcinoma.

Page 905

18F-FMISO pharmacokinetics in NSCLC: Schwartz and colleagues detail the results of pharmacokinetic analysis of 18F-fluoromisonidazole PET extended to 3 h after injection in patients with stage III–IV non–small cell lung cancer.

Page 911

Parametric methods in 18F-FLT PET/CT: Kramer and colleagues validate parametric methods for quantification of 3′-deoxy-3′-18F-fluorothymidine PET in patients with advanced-stage non–small cell lung carcinoma and an activating epidermal growth factor receptor mutation in treatment with gefitinib or erlotinib.

Page 920

Pretargeted α-therapy: Heskamp and colleagues compare the tumor-targeting properties and therapeutic efficacy of 213Bi and 177Lu for pretargeted radioimmunotherapy of carcinoembryonic antigen–expressing xenografts using the bispecific monoclonal antibody TF2 and the di-HSG-DOTA peptide IMP288.

Page 926

Neurotensin receptor–directed theranostics: Fendler and Baum provide perspective on radioligand therapy using agents with high affinity to target specific cell surface receptors in cancer and preview an article on this topic in this issue of JNM.

Page 934

NTR1 theranostics: Schulz and colleagues explore the therapeutic effect of a 177Lu-labeled analog of neurotensin receptor 1−targeting agent 111In-3BP-227 on tumor growth in NTR1-positive HT29 colon carcinoma xenografts.

Page 936

Semiquantitative PSMA PET imaging: Li and colleagues assess variability in normal-organ uptake of 18F-DCFPyL, a small-molecule inhibitor of the prostate-specific membrane antigen, and describe the implications of these findings for biodistribution studies, image interpretation, and therapeutic monitoring.

Page 942

18F- and 68Ga-labeled PSMA tracers: Dietlein and colleagues evaluate the prostate-specific antigen–stratified performance of the 18F-labeled prostate-specific membrane antigen tracer 18F-DCFPyL and the 68Ga-labeled reference 68Ga-PSMA-HBED-CC in patients with biochemical recurrence of prostate cancer.

Page 947

MBF response to arterial CO2: Yang and colleagues investigate whether a physiologically tolerable hypercapnic stimulus can increase myocardial blood flow to levels observed with adenosine in canines without coronary stenosis, with non–flow-limiting stenosis, and after preadministration of caffeine.

Page 953

Valve localization in cardiac SPECT: Betancur and colleagues describe the development of a machine learning approach to automatic mitral valve plane placement, with a resulting decrease in user dependence on SPECT myocardial perfusion imaging quantification.

Page 961

18F-NaF, 18F-FDG, and plaque progression: Li and colleagues analyze associations between inflammation and osteogenesis at different stages of atherosclerosis, as well as the relationships between these two processes during disease progression.

Page 968

18F-JNJ311 as a tau PET ligand: Declercq and colleagues describe the synthesis of this tracer with high affinity for aggregated tau and high in vitro selectivity for tau over β-amyloid and compare it with 18F-AV1451 in preclinical dynamic PET imaging.

Page 975

Evaluation of σ1 PET tracers: Baum and colleagues report on the first PET imaging evaluation in rhesus monkeys of 4 18F-labeled spirocyclic piperidine-based PET radiotracers.

Page 982

Variability of 123I-CLINDE SPECT: Feng and colleagues examine in healthy individuals the test–retest variability of binding for this radiotracer developed for SPECT targeting of the 18-kDa translocator protein.

Page 989

Comparison of THK PET tracers: Betthauser and colleagues compare the in vivo imaging characteristics of the tau PET ligands 18F-THK-5351 and 18F-THK-5317 in patients with Alzheimer disease or genetic predisposition to neurodegenerative disease.

Page 996

Immuno-PET and GvHD: Van Elssen and colleagues detail the development of a method to noninvasively image immune responses in a relevant humanized mouse model of graft-versus-host disease.

Page 1003

MSOT colitis imaging: Bhutiani and colleagues assess in mice the applicability and utility of multispectral optoacoustic tomography for evaluating the presence and severity of colitis.

Page 1009

  • © 2017 by the Society of Nuclear Medicine and Molecular Imaging.
Next
Back to top

In this issue

Journal of Nuclear Medicine: 58 (6)
Journal of Nuclear Medicine
Vol. 58, Issue 6
June 1, 2017
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
This Month in JNM
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
This Month in JNM
Journal of Nuclear Medicine Jun 2017, 58 (6) 8A;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
This Month in JNM
Journal of Nuclear Medicine Jun 2017, 58 (6) 8A;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • 89Zr-Bevacizumab PET: Potential Early Indicator of Everolimus Efficacy in Patients with Metastatic Renal Cell Carcinoma
  • Dose Optimization to Minimize Radiation Risk for Children Undergoing CT and Nuclear Medicine Imaging Is Misguided and Detrimental
  • Noninvasive Imaging of Colitis Using Multispectral Optoacoustic Tomography
  • Rapid Imaging of Tumor Cell Death In Vivo Using the C2A Domain of Synaptotagmin-I
  • Metabolic and Molecular Imaging of Atherosclerosis and Venous Thromboembolism
  • Automatic Valve Plane Localization in Myocardial Perfusion SPECT/CT by Machine Learning: Anatomic and Clinical Validation
  • PET Imaging Evaluation of Four σ1 Radiotracers in Nonhuman Primates
  • PET Imaging for Endocrine Malignancies: From Woe to Go
  • Semiquantitative Parameters in PSMA-Targeted PET Imaging with 18F-DCFPyL: Variability in Normal-Organ Uptake
  • Pharmacokinetic Analysis of Dynamic 18F-Fluoromisonidazole PET Data in Non–Small Cell Lung Cancer
  • Parametric Method Performance for Dynamic 3′-Deoxy-3′-18F-Fluorothymidine PET/CT in Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Carcinoma Patients Before and During Therapy
  • The Variability of Translocator Protein Signal in Brain and Blood of Genotyped Healthy Humans Using In Vivo 123I-CLINDE SPECT Imaging: A Test–Retest Study
  • Intraoperative Assessment of Tumor Resection Margins in Breast-Conserving Surgery Using 18F-FDG Cerenkov Luminescence Imaging: A First-in-Human Feasibility Study
  • Preclinical Evaluation of 18F-JNJ64349311, a Novel PET Tracer for Tau Imaging
  • Arterial CO2 as a Potent Coronary Vasodilator: A Preclinical PET/MR Validation Study with Implications for Cardiac Stress Testing
  • Cumulated Activity Comparison of 64Cu-/177Lu-Labeled Anti–Epidermal Growth Factor Receptor Antibody in Esophageal Squamous Cell Carcinoma Model
  • α- Versus β-Emitting Radionuclides for Pretargeted Radioimmunotherapy of Carcinoembryonic Antigen–Expressing Human Colon Cancer Xenografts
  • Proof of Therapeutic Efficacy of a 177Lu-Labeled Neurotensin Receptor 1 Antagonist in a Colon Carcinoma Xenograft Model
  • NTR Is the New SSTR? Perspective for Neurotensin Receptor 1 (NTR)–Directed Theranostics
  • PSA-Stratified Performance of 18F- and 68Ga-PSMA PET in Patients with Biochemical Recurrence of Prostate Cancer
  • In Vivo Comparison of Tau Radioligands 18F-THK-5351 and 18F-THK-5317
  • Association Between Osteogenesis and Inflammation During the Progression of Calcified Plaque Evaluated by 18F-Fluoride and 18F-FDG
  • Noninvasive Imaging of Human Immune Responses in a Human Xenograft Model of Graft-Versus-Host Disease
  • Wet or Dry? Do Liquid Biopsy Techniques Compete with or Complement PET for Disease Monitoring in Oncology?
  • Prospective Evaluation of Changes in Tumor Size and Tumor Metabolism in Patients with Advanced Gastric Cancer Undergoing Chemotherapy: Association and Clinical Implication
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • This Month in JNM
  • This Month in JNM
  • This Month in JNM
Show more This Month in JNM

Similar Articles

SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire